Table 1 Summary of CVOTs evaluating the cardioranal effects of GLP-1RAs in T2DM
Trial/year of Publication | Study drug/mean follow up (years) | Participants (n) | Age mean (years) | Male sex (n, %) | Participants with established CV disease (n, %) | History of heart failure (n, %) | eGFR < 60 ml/min per 1.73 m2 (n, %) |
|---|---|---|---|---|---|---|---|
ELIXA | Lixisenatide | 6068 | 60.3 | 3174 (69.3%) | 6068 (100%) | 1922 (20.3%) | 1407 (23.2%) |
2015 | 2.1 year | ||||||
LEADER | Liraglutide | 9340 | 64.3 | 6003 (64.3%) | 6764 (72.4%) | 1667 (17.8%) | 2158 (23.1%) |
2016 | 3.8 year | ||||||
SUSTAIN-6 | Semaglutide | 3297 | 64.6 | 2002 (60.7%) | 2735 (83%) | 777 (23.6%) | 939 (28.5%) |
2016 | 3.1 year | ||||||
EXSCEL | Eenatide OW | 14,752 | 62.0 | 9149 (62%) | 10,792 (73.1%) | 2389 (16.2%) | 3191 (21.6%) |
2017 | 3.2 year | ||||||
HARMONY | Albiglutide | 9463 | 64.1 | 6569 (69.4%) | 9463 (100%) | 1922 (20.3%) | NR |
2018 | 1.6 year | ||||||
REWIND | Dulaglutide | 9901 | 66.2 | 5312 (53.7%) | 3109 (31.4%) | 853 (8.6%) | 2199 (22.2%) |
2019 | 5.4 year | ||||||
PIONEER 6 | Semaglutide | 3183 | 66.0 | 2176 (68.4%) | 2695 (84.7%) | 388 (12.2%) | 856 (26.8%) |
2019 | 1.3 year | ||||||
AMPLITUDE-O | Efpeglenatide | 4076 | 64.5 | 2732 (67%) | 3650 (89.6%) | 737 (18.1%) | 1287 (31.6%) |
2021 | 1.8 year |